ISL
REGN icon

Ingalls & Snyder LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Ingalls & Snyder LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-505
Closed -$204K – 437
2018
Q3 		$204K Buy
+505
New +$192K 0.01% 417
2018
Q1 		– Sell
-6,165
Closed -$2.32M – 415
2017
Q4 		$2.32M Sell
6,165
-163
-3% -$66K 0.11% 140
2017
Q3 		$2.83M Sell
6,328
-300
-5% -$143K 0.15% 111
2017
Q2 		$3.25M Buy
6,628
+879
+15% +$385K 0.18% 96
2017
Q1 		$2.23M Buy
+5,749
New +$2.13M 0.12% 127

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ingalls & Snyder LLC's REGN Position: Q4 2018 in Review

Ingalls & Snyder LLC sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 505 shares — an estimated $204K sold.

Ingalls & Snyder LLC first reported a position in REGN in Q1 2017 and held it in 5 quarters. The position peaked at $3.25M in Q2 2017. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

  • Ingalls & Snyder LLC reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 505 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $204K.
  • Ingalls & Snyder LLC first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Ingalls & Snyder LLC's Regeneron Pharmaceuticals position peaked at $3.25M in Q2 2017.
  • 670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Ingalls & Snyder LLC's 13F filing for Q4 2018, filed 24 Jan 2019.